568 related articles for article (PubMed ID: 7504978)
41. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
42. Surgery for testicular cancer: indication, results and technical aspects.
Khouni H; Ghozzi S; Ramzi K; Smaali CH; Majed H; Ben Rais N
Tunis Med; 2005 Dec; 83 Suppl 12():78-83. PubMed ID: 16430075
[TBL] [Abstract][Full Text] [Related]
43. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors.
Toner GC; Geller NL; Tan C; Nisselbaum J; Bosl GJ
Cancer Res; 1990 Sep; 50(18):5904-10. PubMed ID: 1697503
[TBL] [Abstract][Full Text] [Related]
44. Predictive value of marker half-life in relapsed and nonrelapsed nonseminomatous germ cell testicular tumor patients undergoing chemotherapy.
Keskin S; Ekenel M; Başaran M; Bavbek S
Am J Clin Oncol; 2012 Aug; 35(4):369-72. PubMed ID: 22814307
[TBL] [Abstract][Full Text] [Related]
45. [Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer].
Neumann A; Keller T; Jocham D; Doehn C
Aktuelle Urol; 2011 Sep; 42(5):311-5. PubMed ID: 21809268
[TBL] [Abstract][Full Text] [Related]
46. Tumor markers in patients with non-seminomatous germ cell tumors of the testis.
Willemse PH; Sleijfer DT; Schraffordt Koops H; De Bruijn HW; Oosterhuis JW; Brouwers TM; Ockhuizen T; Marrink J
Oncodev Biol Med; 1981; 2(1-2):117-28. PubMed ID: 6170952
[TBL] [Abstract][Full Text] [Related]
47. The predictive value of pre-orchidectomy serum tumor markers in non seminomatous germ cell tumors of the testis (N.S.G.C.T.T.).
Boccon-Gibod L; Le Doze H; Steg A
Prog Clin Biol Res; 1985; 203():93-5. PubMed ID: 2421347
[TBL] [Abstract][Full Text] [Related]
48. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
[TBL] [Abstract][Full Text] [Related]
49. [Plasma lactate dehydrogenase and its isoenzymes in nonseminomatous germ cell tumors of the testis].
Canal P; Villeneuve G; Bugat R; Armand JP; Soula G
Pathol Biol (Paris); 1984 Apr; 32(4):245-50. PubMed ID: 6201806
[TBL] [Abstract][Full Text] [Related]
50. Applications of biologic tumor markers in testicular cancer.
Javadpour N
Cancer Treat Rep; 1979; 63(9-10):1643-7. PubMed ID: 91433
[TBL] [Abstract][Full Text] [Related]
51. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy.
Eastham JA; Wilson TG; Russell C; Ahlering TE; Skinner DG
Urology; 1994 Jan; 43(1):74-80. PubMed ID: 7506856
[TBL] [Abstract][Full Text] [Related]
52. Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study.
Stoter G; Sylvester R; Sleijfer DT; ten Bokkel Huinink WW; Kaye SB; Jones WG; van Oosterom AT; Vendrik CP; Spaander P; de Pauw M
Cancer Res; 1987 May; 47(10):2714-8. PubMed ID: 2436756
[TBL] [Abstract][Full Text] [Related]
53. Serum levels of alpha-fetoprotein, human chorionic gonadotropin and carcinoembryonic antigen in patients with primary intracranial germ cell tumors.
Arita N; Ushio Y; Hayakawa T; Uozumi T; Watanabe M; Mori T; Mogami H
Oncodev Biol Med; 1980; 1(4-5):235-40. PubMed ID: 6169060
[TBL] [Abstract][Full Text] [Related]
54. Lactate dehydrogenase and its isoenzymes in testicular germ cell tumors: an overview.
von Eyben FE
Oncodev Biol Med; 1983; 4(6):395-414. PubMed ID: 6196755
[TBL] [Abstract][Full Text] [Related]
55. Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis.
Horwich A; Peckham MJ
Cancer Treat Rep; 1986 Nov; 70(11):1329-31. PubMed ID: 2429765
[TBL] [Abstract][Full Text] [Related]
56. Diagnosis and treatment of intracranial immature teratoma.
Huang X; Zhang R; Zhou LF
Pediatr Neurosurg; 2009; 45(5):354-60. PubMed ID: 19907199
[TBL] [Abstract][Full Text] [Related]
57. [Testicular tumors--a breakthrough?].
Schmidt CG
Schweiz Med Wochenschr; 1983 Sep; 113(36):1293-300. PubMed ID: 6635628
[TBL] [Abstract][Full Text] [Related]
58. Nonseminomatous germ cell tumors of the testis: current concepts and controversies.
Sheinfeld J
Urology; 1994 Jul; 44(1):2-14. PubMed ID: 7518979
[No Abstract] [Full Text] [Related]
59. Intensive chemotherapy for metastatic nonseminomatous germ cell tumors.
Logothetis CJ; Chong C; Dexeus FH; Sella A; Ogden S
Prog Clin Biol Res; 1990; 350():301-7. PubMed ID: 1696741
[No Abstract] [Full Text] [Related]
60. Surgical outcomes in patients with primary mediastinal non-seminomatous germ cell tumours and elevated post-chemotherapy serum tumour markers.
De Latour B; Fadel E; Mercier O; Mussot S; Fabre D; Fizazi K; Dartevelle P
Eur J Cardiothorac Surg; 2012 Jul; 42(1):66-71; discussion 71. PubMed ID: 22290909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
